Medigus and HC Marbella International Hospital Announce First MUSE™ Procedure for GERD Treatment in Spain
April 17 2018 - 4:05PM
-Leading gastroenterologist reports successful
procedure with comprehensive endoscopic device-
Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a medical device company
developing minimally invasive endosurgical tools and an innovator
in direct visualization technology, along with High Care Marbella
International Hospital, today announced the completion of the first
MUSE procedure in Spain. The procedure was performed by Dr. Victor
Aguilar at HC Marbella International Hospital. Dr. Aguilar reported
that the procedure was successful and the patient was released from
the hospital.
“It’s extremely exciting to see Dr. Aguilar pioneer the
procedure in another key market for the MUSE system,” said Chris
Rowland, Chief Executive Officer of Medigus. “We are looking to
build on the physician interest of the MUSE procedure at Marbella,
and expand availability in other areas of Europe in the
future.”
The MUSE system is a single-use flexible transoral stapler that
merges the latest advancement in microvisual, ultrasonic and
surgical stapling. The device comes equipped with an ultrasonic
sight and range finder and a micro ScoutCam™ CMOS camera, which
enables a single physician to perform an incisionless transoral
fundoplication, the procedure intended to treat the anatomical
cause of gastroesophageal reflux disease (GERD). As the device
requires no incisions, patients generally report greater comfort
during the procedure and experience reduced hospital stays by up to
50% over invasive fundoplication procedures.
“With about fifteen percent of Spain’s population experiencing
GERD on a weekly basisi, I am pleased to lead a procedure that is
addressing a long time need,” said Dr. Aguilar. “The MUSE system
enables me to bring the benefits of an incision-less procedure for
GERD patients as an alternative to drug therapy and invasive
surgical procedures.”
Those who experience symptoms such as heartburn or regurgitation
twice a week or more, may be at risk for persistent GERD.
About MedigusMedigus is a medical device company specializing in
developing minimally invasive endosurgical tools and highly
innovative imaging solutions. They are the pioneer developer of the
MUSE™ system, an FDA cleared and CE marked endoscopic device to
perform Transoral Fundoplication (TF) for the treatment of GERD
(gastroesophageal reflux disease), one of the most common chronic
conditions in the world. In 2016, the CMS established the Category
I CPT® Code of 43210 for TF procedures, such as the ones performed
with MUSE, which establishes reimbursement values for physicians
and hospitals. MUSE is gaining adoption in key markets around the
world – it is available in world-leading healthcare institutions in
the U.S., Europe and Israel. Medigus is also in the process of
obtaining regulatory clearance in China. Medigus is traded on the
Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To
learn more about the company’s advanced technology, please visit
www.medigus.com or www.RefluxHelp.com.
About HC Marbella International Hospital HC Marbella
International Hospital is an exclusive private hospital
delivering high quality medical care located in Costa del
Sol.
Web: www.hcmarbella.com
To learn more about Dr. Aguilar: www.vitalidaddigestiva.com
This press release may contain statements that are
“Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of the company’s management
and its knowledge of the relevant market. The company has tried,
where possible, to identify such information and statements by
using words such as “anticipate,” “believe,” “envision,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” “contemplate” and other similar expressions
and derivations thereof in connection with any discussion of future
events, trends or prospects or future operating or financial
performance, although not all forward-looking statements contain
these identifying words. These forward-looking statements
represent Medigus’ expectations or beliefs concerning future
events, and it is possible that the results described in this press
release will not be achieved. By their nature, Forward-Looking
Statements involve known and unknown risks, uncertainties and other
factors which may cause future results of the company’s activity to
differ significantly from the content and implications of such
statements. Other risk factors affecting the company are discussed
in detail in the Company's filings with the Securities and Exchange
Commission. Forward-Looking Statements are pertinent only as of the
date on which they are made, and the company undertakes no
obligation to update or revise any Forward-Looking Statements,
whether as a result of new information, future developments or
otherwise. Neither the company nor its shareholders, officers and
employees, shall be liable for any action and the results of any
action taken by any person based on the information contained
herein, including without limitation the purchase or sale of
company securities. Nothing in this press release should be deemed
to be medical or other advice of any kind.
MEDIA CONTACT:Chantal BeaudryLazar Partners
Ltd.212-867-1762cbeaudry@lazarpartners.com
i Carlos Martín-de-Argila & Pedro
Martínez-Jiménez (2014) Epidemiological study on the
incidence of gastroesophageal reflux disease symptoms in patients
in acute treatment with NSAIDs, Expert Review of
Gastroenterology &
Hepatology, 7:1, 27-33, DOI: 10.1586/egh.12.61.
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Sep 2023 to Sep 2024